Orchard Therapeutics: Rises after FDA grants 'special' status to gene therapy
14/01/2021 12:49
** Shares of drugmaker Orchard Therapeutics Plc ORTX.O
rise 7% to $6.67 premarket
** U.S. FDA grants Regenerative Medicine Advanced Therapy
(RMAT) designation to co's experimental gene therapy, OTL-200,
for treating Metachromatic leukodystrophy (MLD), a hereditary
disorder that causes fatty substances to build up in cells,
particularly in brain and spinal cord
** OTL-200 has been approved in the European Union for
treating MLD under brand name Libmeldy
** RMAT status is granted to drugs intended to treat,
modify, reverse, or cure a serious or life-threatening disease
or condition and that have shown promise in preliminary clinical
study
** As of Wednesday's close, ORTX shares up ~44% YTD
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln